Aprogen Medicines Inc.

KOSE:A007460 Stock Report

Market Cap: ₩335.7b

Aprogen Medicines Past Earnings Performance

Past criteria checks 0/6

Aprogen Medicines's earnings have been declining at an average annual rate of -15.3%, while the Machinery industry saw earnings growing at 17% annually. Revenues have been growing at an average rate of 12.2% per year.

Key information

-15.3%

Earnings growth rate

14.6%

EPS growth rate

Machinery Industry Growth18.9%
Revenue growth rate12.2%
Return on equity-19.4%
Net Margin-28.6%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Aprogen Medicines Inc. (KRX:007460) May Have Run Too Fast Too Soon With Recent 25% Price Plummet

Sep 29
Aprogen Medicines Inc. (KRX:007460) May Have Run Too Fast Too Soon With Recent 25% Price Plummet

Is Aprogen Medicines (KRX:007460) Using Too Much Debt?

Aug 22
Is Aprogen Medicines (KRX:007460) Using Too Much Debt?

Aprogen Medicines Inc. (KRX:007460) Stock Rockets 41% As Investors Are Less Pessimistic Than Expected

Jul 21
Aprogen Medicines Inc. (KRX:007460) Stock Rockets 41% As Investors Are Less Pessimistic Than Expected

Aprogen Medicines Inc.'s (KRX:007460) 25% Share Price Plunge Could Signal Some Risk

May 31
Aprogen Medicines Inc.'s (KRX:007460) 25% Share Price Plunge Could Signal Some Risk

Is Aprogen Medicines (KRX:007460) A Risky Investment?

May 21
Is Aprogen Medicines (KRX:007460) A Risky Investment?

Aprogen Medicines Inc. (KRX:007460) Investors Are Less Pessimistic Than Expected

Feb 26
Aprogen Medicines Inc. (KRX:007460) Investors Are Less Pessimistic Than Expected

If You Had Bought Aprogen KIC's (KRX:007460) Shares Three Years Ago You Would Be Down 86%

Jan 07
If You Had Bought Aprogen KIC's (KRX:007460) Shares Three Years Ago You Would Be Down 86%

Revenue & Expenses Breakdown

How Aprogen Medicines makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

KOSE:A007460 Revenue, expenses and earnings (KRW Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24147,853-42,27079,97746,763
30 Jun 24150,918-48,70077,89846,763
31 Mar 24152,704-60,05961,62649,520
31 Dec 23150,578-55,61972,24442,817
30 Sep 23150,272-96,92940,43034,196
30 Jun 23138,095-80,20052,40734,196
31 Mar 23107,219-98,80973,19235,294
31 Dec 2278,349-98,65762,62838,561
30 Sep 2247,080-98,93065,15046,125
30 Jun 2226,058-106,30649,08446,125
31 Mar 221,431-110,89137,01650,828
31 Dec 2126,296-93,92043,83332,780
30 Sep 2148,044-90,34039,57923,846
30 Jun 2173,831-36,60620,09924,294
31 Mar 21123,388-42,46828,2021,188
31 Dec 20127,143-46,49028,0361,029
30 Sep 20126,565-47,72026,715850
30 Jun 20117,642-68,78528,318402
31 Mar 20100,987-18,33621,813432
31 Dec 1978,249-10,83914,3731,871
30 Sep 1963,757-5977,6515,900
30 Jun 1952,781-13,0192,5335,900
31 Mar 1952,616-27,5341,5375,835
31 Dec 1851,047-24,9162,8734,381
31 Dec 1740,3764,0282,694364

Quality Earnings: A007460 is currently unprofitable.

Growing Profit Margin: A007460 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: A007460 is unprofitable, and losses have increased over the past 5 years at a rate of 15.3% per year.

Accelerating Growth: Unable to compare A007460's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: A007460 is unprofitable, making it difficult to compare its past year earnings growth to the Machinery industry (4.4%).


Return on Equity

High ROE: A007460 has a negative Return on Equity (-19.4%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies